Polycystic Ovary Syndrome: Impact of Lipotoxicity on Metabolic and Reproductive Health
- PMID: 31344250
- PMCID: PMC6952118
- DOI: 10.1097/OGX.0000000000000661
Polycystic Ovary Syndrome: Impact of Lipotoxicity on Metabolic and Reproductive Health
Abstract
Importance: Polycystic ovary syndrome (PCOS) is the most common endocrinopathy of reproductive-aged women. Women with PCOS are at increased risk of developing several metabolic and reproductive abnormalities, including metabolic syndrome. Underlying the combined metabolic and reproductive dysfunction is lipotoxicity, defined as the ectopic deposition of lipid in nonadipose tissue where it induces oxidative stress linked with insulin resistance and inflammation.
Objective: To examine what metabolic components underlie insulin resistance in PCOS, how lipotoxicity through insulin resistance impairs metabolism and reproduction in these women, and why evidence-based, individualized management is essential for their care.
Evidence acquisition: PubMed search was performed using relevant terms to identify journal articles related to the subject. Relevant textbook chapters were also used.
Results: Polycystic ovary syndrome by Rotterdam criteria represents a complex syndrome of heterogeneous expression with variable adverse metabolic and reproductive implications. Women with classic PCOS are often insulin resistant and at greatest risk of developing metabolic syndrome with preferential fat accumulation and weight gain. Moreover, PCOS women may also have an altered capacity to properly store fat, causing ectopic lipid accumulation in nonadipose tissue, including the ovaries, where it can perpetuate insulin resistance and inflammation and harm the oocyte.
Conclusions and relevance: A personalized approach to managing PCOS is essential to improve the health of all PCOS women through cost-effective prevention and/or treatment, to minimize the risk of pregnancy complications in those individuals wishing to conceive, and to optimize the long-term health of PCOS women and their offspring.
Conflict of interest statement
Authors have no conflict of interest to report.
Figures

Similar articles
-
POLYCYSTIC OVARY SYNDROME: ORIGINS AND IMPLICATIONS: Polycystic ovary syndrome: an evolutionary metabolic adaptation.Reproduction. 2025 Mar 24;169(4):e250021. doi: 10.1530/REP-25-0021. Print 2025 Apr 1. Reproduction. 2025. PMID: 40080428 Review.
-
Polycystic ovary syndrome: a complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan.BMC Med. 2010 Jun 30;8:41. doi: 10.1186/1741-7015-8-41. BMC Med. 2010. PMID: 20591140 Free PMC article. Review.
-
A Narrative Review of Placental Contribution to Adverse Pregnancy Outcomes in Women With Polycystic Ovary Syndrome.J Clin Endocrinol Metab. 2019 Nov 1;104(11):5299-5315. doi: 10.1210/jc.2019-00383. J Clin Endocrinol Metab. 2019. PMID: 31393571 Free PMC article. Review.
-
An Evolutionary Model for the Ancient Origins of Polycystic Ovary Syndrome.J Clin Med. 2023 Sep 22;12(19):6120. doi: 10.3390/jcm12196120. J Clin Med. 2023. PMID: 37834765 Free PMC article.
-
Polycystic ovaries are common in women with hyperandrogenic chronic anovulation but do not predict metabolic or reproductive phenotype.J Clin Endocrinol Metab. 2005 May;90(5):2571-9. doi: 10.1210/jc.2004-0219. Epub 2005 Feb 15. J Clin Endocrinol Metab. 2005. PMID: 15713728
Cited by
-
Acetate ameliorates ovarian mitochondrial dysfunction in letrozole-induced polycystic ovarian syndrome rat model by improving mitofusin-2.J Physiol Sci. 2024 Apr 1;74(1):22. doi: 10.1186/s12576-024-00908-5. J Physiol Sci. 2024. PMID: 38561673 Free PMC article.
-
Accelerated subcutaneous abdominal stem cell adipogenesis predicts insulin sensitivity in normal-weight women with polycystic ovary syndrome.Fertil Steril. 2021 Jul;116(1):232-242. doi: 10.1016/j.fertnstert.2020.10.003. Epub 2020 Dec 17. Fertil Steril. 2021. PMID: 33341231 Free PMC article.
-
The Subcutaneous Adipose Microenvironment as a Determinant of Body Fat Development in Polycystic Ovary Syndrome.J Endocr Soc. 2024 Sep 17;8(11):bvae162. doi: 10.1210/jendso/bvae162. eCollection 2024 Sep 26. J Endocr Soc. 2024. PMID: 39345868 Free PMC article.
-
miR-4433a-3p promotes granulosa cell apoptosis by targeting peroxisome proliferator-activated receptor alpha and inducing immune cell infiltration in polycystic ovarian syndrome.J Assist Reprod Genet. 2023 Jun;40(6):1447-1459. doi: 10.1007/s10815-023-02815-x. Epub 2023 May 19. J Assist Reprod Genet. 2023. PMID: 37204637 Free PMC article.
-
Hydroxychloroquine enhances insulin sensitivity and ameliorates abnormal lipid metabolism in obese women with polycystic ovary syndrome.BMC Endocr Disord. 2025 Jan 2;25(1):2. doi: 10.1186/s12902-024-01827-7. BMC Endocr Disord. 2025. PMID: 39748269 Free PMC article. Clinical Trial.
References
-
- Zawadzki JK DA. Diagnostic criteria for polycystic ovary syndrome: Toward a rational approach. Boston, MA: Blackwell Scientific; 1992
-
- Rotterdam EA-SPCWG. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004;81:19–25 - PubMed
-
- Azziz R, Carmina E, Dewailly D, et al. The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Fertil Steril 2009;91:456–488 - PubMed
-
- Chang RJ DD. Polycystic Ovary Syndrome and Hyperandrogenic States. Philadelphia: Elsevier Saunders; 2018
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical